Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer

European Journal of Cancer

Volumn 47, Issue 8, 2011, Pages 1146-1151

  Hawkes, Eliza ^a   Okines, Alicia F C ^a   Papamichael, Demetris ^b   Rao, Sheela ^a   Ashley, Sue ^a   Charalambous, Haris ^b   Koukouma, Alona ^b   Chau, Ian ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Bank of Cyprus Group Oncology Centre   (Cyprus)

Author keywords

Chemotherapy; Docetaxel; Irinotecan; Oesophagogastric cancer; Second line

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEMCITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ACUTE RESPIRATORY TRACT DISEASE; ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LOWER ESOPHAGUS SPHINCTER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COHORT STUDIES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 79955534227     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.12.021     Document Type: Article

References (20)

1. Cancer Research, UK. http://info.cancerresearchuk.org/cancerstats/ incidence/index.htm. London, UK; 2010.
2. B. Glimelius, K. Ekstrom, and K. Hoffman Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer Ann Oncol 8 1997 163 168 (Pubitemid 27112884)
3. A.D. Wagner, S. Unverzagt, and W. Grothe Chemotherapy for advanced gastric cancer Cochrane Database Syst Rev 3 2010 CD004064
4. Y. Kodera, S. Ito, and Y. Mochizuki A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study) Anticancer Res 27 2007 2667 2671 (Pubitemid 47227980)
5. J.L. Lee, M.H. Ryu, and H.M. Chang A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy Cancer Chemother Pharmacol 61 2008 631 637
6. J.H. Chun, H.K. Kim, and J.S. Lee Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy Jpn J Clin Oncol 34 2004 8 13 (Pubitemid 43118052)
7. L. Assersohn, G. Brown, and D. Cunningham Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma Ann Oncol 15 2004 64 69 (Pubitemid 38145530)
8. A. Leary, L. Assersohn, and D. Cunningham A phase II trial evaluating capecitabine and irinotecan as second-line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy Cancer Chemother Pharmacol 64 2009 455 462
9. Thuss-Patience PKA, Deist T, Hinke A, Bichev D, Lebedinzew B, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer - a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer vol. 7, No. 2, Joint ECCO 15-34th ESMO Multidisciplinary Congress; 2009.
10. S.J. Sym, H.M. Chang, and H.J. Kang A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer Cancer Chemother Pharmacol 63 2008 1 8
11. B. Burtness, M. Gibson, and B. Egleston Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer Ann Oncol 20 2009 1242 1248
12. D. Cunningham, N. Starling, and S. Rao Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
13. E. Van Cutsem, V.M. Moiseyenko, and S. Tjulandin Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 24 2006 4991 4997 (Pubitemid 46631401)
14. N.C. Tebbutt, M.M. Cummins, and T. Sourjina Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial Br J Cancer 102 2010 475 481
15. C.H. Kohne, R. Catane, and B. Klein Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial Br J Cancer 89 2003 997 1001 (Pubitemid 37239201)
16. F.S. Farhat A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer Med Oncol 24 2007 137 146 (Pubitemid 350139221)
17. E. Bleickardt, A. Argiris, and R. Rich Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer Cancer Biol Ther 1 2002 646 651
18. R. Govindan, W. Read, and J. Faust Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report Oncology (Williston Park) 17 2003 27 31
19. F. Lordick, C. von Schilling, and H. Bernhard Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer Br J Cancer 89 2003 630 633 (Pubitemid 37076164)
20. E.K.Y. Van Cutsem, H. Chung, and L. Shen Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol 27 2009 LBA4509